Eddie Hickman
Stock Analyst at Guggenheim
(3.76)
# 694
Out of 5,154 analysts
21
Total ratings
80%
Success rate
34.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $87 → $90 | $73.26 | +22.85% | 10 | Feb 25, 2026 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $23.40 | +49.57% | 4 | Feb 6, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $11 | $3.39 | +224.48% | 1 | Jan 20, 2026 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.41 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.98 | +144.99% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $15.93 | +100.88% | 1 | Mar 13, 2025 |
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $87 → $90
Current: $73.26
Upside: +22.85%
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $23.40
Upside: +49.57%
AtaiBeckley
Jan 20, 2026
Initiates: Buy
Price Target: $11
Current: $3.39
Upside: +224.48%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.41
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.98
Upside: +144.99%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $15.93
Upside: +100.88%